Introduction

Colorectal cancer (CRC) remains the third most common malignancies among men and women in the United States according to Colorectal Cancer Statistics, 2017 [1]. During past several decades, overall incidence and mortality of CRC are declining significantly across population over the age of 50 years in the United States. It may largely attribute to the introduction and implement of cancer screening, healthier lifestyle, and advanced therapies [2–4].

According to Survivorship Statistics released by American Cancer Society, it is estimated that more than 15 million survivors are living in the United States with a previous colorectal cancer diagnosis in 2016 [5]. A large body of literatures reported the increased risk of second primary
malignancies among population with certain prior cancers, including CRC [6–10]. Several population-based studies had validated that a history of prior CRC was a known risk factor for developing second malignancies subsequently in relation to the general population [11–14]. Although the clear mechanism underlying this trend remained unknown, a possible combination of genetic predisposition, risk exposures, and cytotoxic effects of chemotherapy, radiotherapy could be at play [15–21]. Currently, the worrying trend of increasing rate of young-onset CRC has been reported and warned by recent literature [22–24]. Considering longer life expectancy of young patients, it is plausible that the likelihood of developing a second primary malignancy later in life would become larger. Several studies had indicated that young CRC survivors are predisposed to subsequent cancers [25–27].

Therefore, the issue regarding the risk of SPCs in the young needs to be further explored. We performed a retrospective population-based study to quantify the risk and characterize site-distribution patterns of SPCs in the young to address this important gap. From a clinical perspective, it is critical to understand and characterize patterns of SPCs among young survivors in order to provide the appropriate surveillance strategies for these populations.

Method

Data source and population

We conducted this retrospective study by utilizing the National Cancer Institute’s (NCI’s) Surveillance, Epidemiology, and End Results (SEER) database, which approximately cover 28% of the United States population [28]. The SEER program routinely collects the high-quality demographic, clinical, and follow-up information from 18 cancer registries. Current data retrieved from SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013) <Katrina/Rita Population Adjustment> (nine registries including San Francisco–Oakland SMSA, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta) [29]. Patients age ≥18 years, who were diagnosed with first primary microscopically confirmed colon and rectum cancer (SEER code, site recode B ICD-O-3/WHO 2008) between 1973 and 2013, were included in this selected cohort. We excluded cases with CRC that was identified by death certificate or autopsy only. To insure that synchronous primary malignancies were not classified as second primary cancers, we included cases with at least 6-months latency restriction (period between the time of primary CRC diagnosis and the time of a second cancer diagnosis). We also conducted sensitivity analyses further excluding cases diagnosed within CRC before a year. Considering the fact that average-risk screening is recommended to begin at 50 years of age by American Cancer Society, we defined patients aged ≤50 years as young survivors and cases aged >50 years as old survivors at the time of diagnosis. For tumor subsites, we divided patients into three groups by primary site-labeled: proximal colon (C18.0, C18.2–C18.4), distal colon (C18.5–C18.7), rectum (C19.9, C20.9). Other sites (C18.8, C18.9, C26.0) were coded as unclear. Our study was approved by the review board of Zhejiang Institute of Gastroenterology, Sir Run Run Shaw Hospital, China.

Statistical analyses

Multiple primary-standardized incidence ratios (MP-SIR) sessions of SEER*Stat version 8.3. (SEER Program,
National Cancer Institute) were adopted to calculate standardized incidence ratios (SIRs) and absolute excess risk (AER). The SIR, also known as the relative risk, is calculated by dividing the observed number of second cancers by the expected number of cancers [observed/expected (O/E) ratio] in the general population without primary malignancies. AER was defined as the excess cancer per 10,000 persons per year, which is an absolute measure of the clinical burden of additional cancer [30]. More detailed information about SEER*Stat software and the methods are available on the SEER-registry website (https://seer.cancer.gov/resources/). SIRs for subgroup analysis were further stratified by gender (male and female), race (White, Black, American Indian/Alaska Native, Asian or Pacific Islander), calendar year (1973–1983, 1984–1993, 1994–2003, 2004 + ), latency period after first CRC diagnosis (6–11, 12–59, 60–119, 120 + months), SEER stage (localized, regional, distant), cancer subsite (proximal, distal colon, rectum), radiotherapy (radiation, no radiation). Additionally, we also assessed the cause of death among young survivors to elucidate influence of second cancers in their prognosis. We defined the cause of death based on the cause of death (COD) to site recode in the SEER. Furthermore, we adopted standardized mortality ratios (SMRs) to compare the relative risk of death for patients with CRC in relation to general US population. All statistical tests of significance were two-sided, and a \( P \) value <0.05 was considered statistically significant.

**Results**

Totally, 44,106 CRC survivors, including 3,245 (7.4%) young and 40,861 (92.6%) old survivors, were included in this study. They developed 50,679 SPCs at least 6 months after the original diagnosis. Characteristics of those patients were summarized in Table 1. The total observation period...
was 2,474,945.72 person-years with a mean of 7.31 person-years at risk. Regardless of detailed sites of secondary cancers, the overall SIR was inversely associated with age of onset (Fig. 1A). The absolute excess risk was also markedly elevated for young population, especially for individuals aged between 25 and 45 years (Fig. 1B). Compared with general population, young survivors were at increased risk of all solid tumors, while no significant SIR of hematological disease was observed (Fig. 2). The SIRs of all sites, all solid tumors, hematological disease were 1.44, 1.47, 1.01 times higher for young survivors and 1.02, 1.05, 0.91 times for old groups (Table S1). The AER of all sites, all solid tumors, hematological disease were 34.23, 33.07, 0.06 excess risk per 10,000 persons per year for young groups, while 4.29, 8.92, −1.75 excess risk for old patients (Table S1). For site-distribution patterns of SPCs, there were several significant differences across young and old survivors (Fig. 3). In the young, the excess risk was observed for subsequent noncolonic cancers of small intestine (SIR, 8.49, 95% CI = 6.93–10.28), bile ducts (SIR, 3.77, 95% CI = 2.76–5.03), corpus and uterus (SIR, 2.45, 95%  

Figure 3. Standardized incidence ratios for subsequent primary malignancies in different sites by age group. SPCs, second primary cancers. *P < 0.05 (compared with general population).
Figure 4. Standardized incidence ratios and absolute excess risk for subsequent cancers in different sites among young and old survivors by gender, race, year, stage, subsites, latency, therapy group. (A) standardized incidence interval; (B) absolute excess risk. m, month, AI/AN, American Indian and Alaska Native; AP, Asian or Pacific Islander. *P < 0.05 (compared with general population).
CI = 2.14–2.79, for female), stomach (SIR, 2.31, 95% CI = 1.86–2.83), soft tissue including heart (SIR, 1.59, 95% CI = 1.02–2.37), pancreas (SIR, 1.62, 95% CI = 1.32–1.97), ovary (SIR, 1.51, 95% CI = 1.17–1.93, for female), thyroid (SIR, 1.48, 95% CI = 1.18–1.84), kidney (SIR, 1.37, 95% CI = 1.13–1.65), urinary bladder (SIR, 1.32, 95% CI = 1.12–1.56) (Table S1). In contrast, a slightly increased risk for SPCs of small intestine (SIR, 2.76, 95% CI = 2.52–3.02), thyroid (SIR, 1.26, 95% CI = 1.13–1.40), bile ducts (SIR, 1.20, 95% CI = 1.07–1.33), stomach (SIR, 1.11, 95% CI = 1.05–1.18), corpus and uterus (SIR, 1.10, 95% CI = 1.04–1.17), esophagus (SIR, 1.10, 95% CI = 1.01–1.20) were found in old population (Table S1).

Furthermore, we conducted subgroup analysis to determine whether the SIRs of SPCs were consistent in subgroups. The significant increased SIRs, AER of SPCs were observed in young population regardless of different variables (Fig. 4A and B). For different gender, young male survivors were at significant risk for SPCs of small intestine compared with female young survivors (Table S2). For different race, the highest risk for SPCs belongs to American Indian/Alaska Native (AI/AN) in both young and old survivors (Table S3). In young survivors, compared with White and Black people, AP and AI/AN had dramatically higher risk of SPCs and the magnitude was huge. The most common sites for SPCs in young AI/AN patients were colon, stomach, and ovary, which was in contrast with old AI/AN patients. For different calendar periods, the risk of SPCs in young survivors elevated significantly and gradually from 1973–1983 to 2004–2013 (Table S4). Among old population, the elevated risk was only noted during the period between 1994–2003 and 2004–2013. For different stages, the risk of all sites SPCs increased gradually among young survivors from localized, regional to distant stage, whereas the risk for SPCs of all

Figure 5. Survival outcomes and cause of death among young and old patients. (A) survival outcomes of young and old patients; (B) cause of death (primary cancer, second cancer, and other causes) among young and old patients *P < 0.05 (compared with general population).
sites significantly reduced in old survivors (Table S5). This might be due to short survival period of old patients with CRC. For different subsites, in young survivors, the highest SIR of all sites SPCs was observed in proximal colon cancer compared with distal colon and rectum cancer (Table S6). In old survivors, patients with rectum cancer even had decreased overall risk of SPCs. For different latency, significant risk of SPCs was centered in initial 5 years after primary diagnosis among young survivors and even after 10 years (Table S7), the risk still be significantly higher for SPCs of small intestine, colon, rectum, kidney, stomach, bile ducts, urinary bladder. In old population, slightly increased risk of SPCs was only centered in initial 5 years and decreased with time. For patients who did and did not receive radiation, there was no different risk of all sites SPCs in young groups. Receipt of radiation did not lead to a higher risk of SPCs (Table S8).

As Figure 5A illustrated that 50.76% of young patients died and more than 79% of old patients died during follow-up period. As Figure 5B shown, secondary cancers were responsible for 51.2% of all deaths in young survivors, while 44.5% deaths were caused by subsequent cancers in old survivors. Furthermore, we selected several cancer types as common cause of deaths due to SPCs. Compared with general US population, young CRC survivors were at excessive risk of death caused by secondary stomach, liver and bile, pancreas, lung and bronchus, melanoma, corpus and uterus, prostate, kidney and renal pelvis, brain, and other nervous system (Fig. 6). However, a slightly increased risk of death due to secondary esophagus, stomach, liver and bile, pancreas, lung and bronchus, corpus, and uterus was observed (Fig. 6). There was a decreased risk of death due to secondary prostate, breast, melanoma, lymphoma among old groups (Fig. 6).

Discussion

In view of notable uptrend of young-onset CRC, growing numbers of young survivors are at risk of SPCs. Our study supported the conclusions of previous literatures that a prior CRC history increased incidence of secondary malignancies [25, 31]. In current study, we observed several notable and interesting findings. First, there was a strong inverse association between age and risk of SPCs. The largest SIR and AER were concentrated in aged 20–40 years. Secondly, compared with the US general population, young survivors had a significantly 44% higher SIR of all sites, while the SIR (2%) for old patients was only slightly increased. Thirdly, we provided further detail on the site-distribution patterns of additional cancers occurring in young survivors. The small intestine, stomach, corpus and

![Figure 6. Standardized mortality ratios for secondary cancer types among young and old cancer survivors. *P < 0.05 (compared with general population).](image-url)
uteros, colon, rectum, and bile ducts were the most six common sites for second primary malignancies. Fourthly, significant increased risk of death due to second cancers was observed in young survivors. Compared with general population, young survivors with subsequent stomach, liver and bile, pancreases, and corpus and uterus had higher mortality. Our analysis extends current understanding of the risk of SPCs that young cancer survivors faced.

Previous studies also addressed some aspects of this issue. For example, Liang et al. [27] demonstrated that compared with the general population, young patients in Taiwan (aged <50 years) had higher risk of SPCs (SIR = 2.52, 95%CI, 2.28–2.78), although the SIR for all patients was nonsignificant. Besides, they observed that the most common sites for SPCs in young patients included the small intestine, large intestine, female genital organs, and the lungs. In our cohort, we did not observe the significant risk for lung and bronchus in young groups. It might be due to different population. Although the clear reasons for increasing risk of SPCs among young population are not well understood, they may be attributed in part to the genetic and environmental factors, including additional therapy-related factors, such as radiation and chemotherapy agents [10]. Previous studies indicated that patients who received radiation seemed especially prone to develop second malignancies [32]. However, in current study, radiotherapy did not significantly increase the risk of all sites SPCs in both young and old patients, except for urinary bladder. As we known, hereditary predisposition and family history may be involved in development of CRC, particularly pronounced for young-onset CRC, such as Lynch syndrome (also termed hereditary nonpolyposis colorectal cancer, HNPCC). Lynch syndrome is an inherited disorder that is due to defects in DNA mismatch repair genes (such as MLH1, MSH2, MSH6, PMS2, or EPCAM) [33]. Those patients were predisposed to develop multiple malignancies in the colorectal, small intestine, stomach, hepatobiliary tract, as well as extragynecic sites including endometrial, ovary, upper urinary tract, brain, and skin [10, 34, 35].

The results presented here should be interpreted cautiously when considering intrinsic limitations of our study. First, due to inherent limitation of SEER database, we were unable to control several cancer risk factors and treatment-related factors such as chemotherapy, which may introduce some bias. Secondly, we included data from nine registries in SEER because only nine registries were included at first since 1973. Thirdly, we were unable to exclude the possibility of synchronous primary cancers or metastases. Nonetheless, our sensitivity analysis indicated that the overall results were not substantial altered when we excluded patients diagnosed within 1 year of prior CRC (data not shown).

Despite these limitations, our analysis indicated that young CRC survivors had significantly excess risk of SPCs in relative to the general population. Additional studies from other centers need to verify this trend. A comprehensive understanding of the risk faced by young survivors with a history of colorectal cancer would help to determine appropriate prevention strategies. If a true relationship between high risk of SPCs and young age of survivors does exist, young age of onset CRC might imply the need of regular surveillance and monitoring.

Acknowledgment

We thank Ms. Dong Wenjie for revisions of our manuscript.

Conflict of Interest

No potential conflict of interests to declare.

References

1. Siegel, R. L., K. D. Miller, and A. Jemal. 2017. Cancer statistics, 2017. CA Cancer J. Clin. 67:7–30.
2. Edwards, B. K., E. Ward, B. A. Kohler, C. Ehemann, A. G. Zauber, R. N. Anderson, et al. 2010. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116:544–573.
3. Siegel, R. L., S. A. Fedewa, W. F. Anderson, K. D. Miller, J. Ma, P. S. Rosenberg, et al. 2017. Colorectal cancer incidence patterns in the United States, 1974-2013. J. Natl Cancer Inst. 109(8).
4. Siegel, R. L., K. D. Miller, S. A. Fedewa, D. J. Ahnen, R. G. S. Meester, A. Barzi, et al. 2017. Colorectal cancer statistics, 2017. CA Cancer J. Clin. 67:177–193.
5. Miller, K. D., R. L. Siegel, C. C. Lin, A. B. Mariotto, J. L. Kramer, J. H. Rowland, et al. 2016. Cancer treatment and survivorship statistics, 2016. CA Cancer J. Clin. 66:271–289.
6. Marti, J. L., K. S. Jain, and L. Morris. 2015. Increased risk of second primary malignancy in pediatric and young adult patients treated with radioactive iodine for differentiated thyroid cancer. Thyroid 25:681–687.
7. Davis, E. J., J. L. Beebe-Dimmer, C. L. Yee, and K. A. Cooney. 2014. Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study. Cancer 120:2735–2741.
8. Chuang, S. C., G. Scélo, Y. C. A. Lee, S. Friis, E. Pukkala, D. H. Brewster, et al. 2010. Risks of second primary cancer among patients with major histological
High Risk of SPCs in Young CRC Patients

1. Willett, W. C. 2005. Diet and cancer: an evolving picture. JAMA 293:233–234.
2. The Lancet Oncology. 2017. Colorectal cancer: a disease of the young? Lancet Oncol. 18:413.
3. Murphy, C. C., H. K. Sanoff, K. B. Sitzenberg, J. A. Baron, J. L. Lund, and R. S. Sandler. 2017. Patterns of epidemiologic and clinicopathologic characteristics of stages II and III colorectal cancer patients by age: examining potential mechanisms of young-onset disease. J. Cancer Epidemiol. 2017:4024580.

4. Bhandari, A., M. Woodhouse, and S. Gupta. 2017. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J. Investig. Med. 65:311–315.

5. Lee, Y. T., C. J. Liu, Y. W. Hu, C. I. Teng, C. H. Tzeng, C. M. Yeh, et al. 2015. Incidence of second primary malignancies following colorectal cancer: a distinct pattern of occurrence between colon and rectal cancers and association of co-morbidity with second primary malignancies in a population-based cohort of 98,876 patients in Taiwan. Medicine (Baltimore). 94:e1079.

6. Youlden, D. R., and P. D. Baade. 2011. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer 11:83.

7. Liang, Y. H., Y. Y. Shao, H. M. Chen, C. L. Lai, Z. Z. Lin, R. N. Kuo, et al. 2015. Young patients with colorectal cancer have increased risk of second primary cancers. Jpn. J. Clin. Oncol. 45:1029–1035.

8. National Cancer Institute Surveillance E, and End Results Program. Overview of the SEER program. Available at http://seer.cancer.gov/about/overview.html.

9. Surveillance, E., and End Results (SEER) Program, Surveillance Systems Branch, National Cancer Institute, DCCPS, Surveillance to County Attributes - Total U.S., 1969-2014 Counties, <Katrina/Rita Population Adjustment> - Linked - SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) Available at http://seer.cancer.gov/about/overview.html.

10. Rothman, K. J., and J. D. Boice. 1979. Epidemiologic analysis with a programmable calculator. Pp. 79–649. US Government Printing Office, NIH publication, Washington DC.

11. Shureiqi, I., C. D. Cooksley, J. Morris, A. S. Soliman, B. Levin, and S. M. Lippman. 2001. Effect of age on risk of second primary colorectal cancer. J. Natl. Cancer Inst. 93:1264–1266.

12. Warschikow, R., U. Guller, T. Cerny, B. M. Schmied, L. Plasswilm, and P. M. Putora. 2017. Secondary malignancies after rectal cancer resection with and without radiation therapy: a propensity-adjusted,
population-based SEER analysis. Radiother. Oncol. 123:139–146.
33. Rumilla, K., K. V. Schowalter, N. M. Lindor, B. C. Thomas, K. A. Mensink, S. Gallinger, et al. 2011. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. J. Mol. Diagn. 13:93–99.
34. Aarnio, M., R. Sankila, E. Pukkala, R. Salovaara, L. A. Aaltonen, A. de la Chapelle, et al. 1999. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int. J. Cancer 81:214–218.
35. Watson, P., and H. T. Lynch. 1993. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677–685.

**Supporting Information**

Additional supporting information may be found in the online version of this article:

**Table S1.** Cancer site-specific standardized incidence ratios and absolute excess risk of a Second Primary Cancers (SPCs) for young and old survivor with prior diagnosis of colorectal cancer.

**Table S2.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by gender.

**Table S3.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by race.

**Table S4.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by year.

**Table S5.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by SEER stage.

**Table S6.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by colorectal cancer subsite.

**Table S7.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by latency.

**Table S8.** Cancer site-specific Standardized Incidence Ratios (SIRs) for second primary cancer by radiation.